

The Executive Office of Health & Human Services

Pharmacy and Therapeutics Committee Meeting Minutes



Tuesday, June 8th, 2021

8:00 AM

Gainwell Technologies

Location: Virtual

P & T Members Present: Greg Allen, MD
Todd Brothers, PharmD
Nickolai Morin, PharmD
Bill Quirk, RPh
Matt Salisbury, MD
Tracey Taviera, PharmD
Rick Wagner, MD

Absent: Dezeree Hodish, Assistant Director Financial and Contract Management (EOHHS)

Others Present: Ann Bennett, MHA (Gainwell Technologies)
Jerry Fingerut, MD, Medical Director, (EOHHS)
Karen Mariano, RPh (Gainwell Technologies)
Kathryn Novak, RPh (Magellan Medicaid Administration)

The meeting was called to order by the Chairperson once a quorum was in attendance - 8:06 am. Chairman Tracey Taviera called the meeting to order and asked for introductions the committee and those supporting the meeting. The April 13th, 2021 meeting minutes were reviewed and by vote were accepted as presented. Co-chair Todd Brothers reviewed the current by-laws and led the discussion for recommended changes.

Article	Section	Item	Recommendation	Discussion
III	I		Change "physician" to "prescriber"	Goal to expand and include RNPs and PA. Karen Mariano will follow up on verbiage change.
II	IV		Disclose any ad-hoc medical specialists to committee 48 hours prior to the meeting Virtual attendance if committee member unable to attend in person.	Provide advance notice of specialist attendance Clarification necessary if permitted by RI Open Meetings. Karen Mariano will follow up.
VI	I	1 & 2	Add text Registration 10 days prior to meeting; if providing public testimony the speaker must register on their own	Provide sufficient advance of speakers/topic
	II	8	Committee advise to speakers regarding public testimony	Avoid presentation of previously published data or package insert details; target novel or updated product information.

Public testimony included the following speakers and topics.

Follow up information should be sent to karen.mariano@gainwelltechnologies.com for distribution to the committee.

P & T Speakers	Affiliation	Topic
Jane Guo	Novartis	Cosentyx
Yuen Yee Ho	Pfizer	Xeljanz
Paul Isikwe	Teva	ArmonAir Digihaler & Airduo Digihaler
Kristin Kollecas	Sanofi Genzyme	Dupixent
Kerri Wolfe	Genentech	Xofluza
Maureen Mealy	Horizon Therapeutics	Uplinza

Magellan Medicaid Administration (MMA) presented the following categories for therapeutic class reviews with discussion from the pharmacy and therapeutics committee.

Therapeutic Categories			Comments & Discussion	Vote:Yes	Vote:No	Abstain	Motion	
Anti-Infectives	Antibiotics	GI	Alinia available as generic; brand was non rebatable. Compliance is at 88%. Recommendation to add vancomycin authorized generic (AG) and vancomycin caps.	x			pass	
		Vaginal	Expanded indication for Vandazole. Compliance is at 87%. No changes recommended.	x			pass	
	Antifungals	Oral	No recent/new clinical information. Compliance is at 98%. No changes recommended.	x			pass	
	Antivirals	HSV	No recent/new clinical information. Compliance is at 98%. No changes recommended.	x			pass	
		Influenza	Xofluza has new indications. There is no utilization. No changes recommended. Motion & discussion: add Xofluza; compliance benefit of 1 day use. Question regarding impact of adding product to PDL? Original recommendation are most cost effective for State. Discussion/advocate knowing resistance before adding to PDL. RI FFS can add in case of public health issue. Can we delay looking at addition until later in the year/season. Motion made to accept the category as originally presented.	x			pass	
	Cephalosporins & Related		No recent/new clinical information. Compliance is at 99%. No changes recommended.	x			pass	
	Fluroquinolones		ACP issued best practice advice for ST use of AB for common infections. No changes recommended.	x			pass	
	Hepatitis C Agents		No recent/new clinical information. No changes recommended.	x			pass	
	HIV Agents		All oral products recommended as preferred. Discussion; what have other state done with category? Some are like RI. Others cover generics first, single tablet management or cover a single PREP.	x			pass	
	Macrolides & Related		IDSA ANN ACRA guidelines on prevention treatment Lyme. No changes recommended.	x			pass	
	Tetracyclines	Oral	No recent/new clinical information. Compliance is at 95%. No changes recommended.	x			pass	
	Dermatological	Acne Agents	Topical	No recent/new clinical information. Compliance is at 65%. No changes recommended.	x			pass
		Antibiotics	Topical	No recent/new clinical information. Compliance is at 86%. No changes recommended.	x			pass
		Antifungals	Topical	No recent/new clinical information. Compliance is good. No changes recommended.	x			pass
Antipsoriatics		Topical	No recent/new clinical information. Compliance is good. No changes recommended.	x			pass	
Antiviral Agents		Topical	No recent/new clinical information. No utilization. No changes recommended.	x			pass	
Immunomodulators		Atopic Dermatitis	No recent/new relevant clinical information; recommend add Eucrisa; requires failure on 1 topical anti-inflammatory/steroids in past 3 months	x			pass	
Rosacea Agents		Topical Summary	No recent/new clinical information. No utilization. No changes recommended.	x			pass	
			No recent/new clinical information. Utilization is low. No changes recommended.	x			pass	
Steroids	Topical	There are 4 sub-categories; one updated indication for Ultravate for plaque psoriasis for 12 yo; compliance is >90% except ultra high with is 82%. No recommended changes to any of the 4 sub-categories.	x			pass		

Therapeutic Categories (cont.)		Comments & Discussion	Vote:Yes	Vote:No	Abstain	Motion
Immunologic	Cytokine & CAM Antagonists	Updated information: Xeljanz, Arcalast, Kineret, Humira; FDA preliminary safety alert with Xeljanz compared to TNF inhibitors. Compliance is at 70%. No changes recommended.	x			pass
	Methotrexate Agents	No recent/new clinical information. Compliance is 100%. No changes recommended.	x			pass
Respiratory	Anti-allergens	Oral	Ragwitek has new indication 5yo; many products not rebate eligible; some agents injections; nothing in category to be preferred.	x		pass
	Antibiotics	Inhaled	No recent/new clinical information. Compliance is good. No changes recommended.	x		pass
	Antihistamines	Minimally Sedating	No recent/new clinical information. Compliance is at 96%. No changes recommended.	x		pass
	Bronchodilators	Beta Antagonists	No recent/new clinical information. Compliance as at 54.8%. Recommended change to non-prefer generic Proventil HFA (AG) formulation.	x		pass
	COPD Agents		Recommend addition of Anoro Ellipta and non-prefer Bevespi Aerosphere; no utilization of Bevespi.	x		pass
	Epinephrine	Self-Injected	No recent/new clinical information. Periodic supply availability issues. No changes recommended.	x		pass
	Glucocorticoids	Inhaled	Trelegy Ellipta updated information 18 yo asthma. Recommend addition of budesonide(generic) respules and non-prefer Pulmicort (brand).	x		pass
		Oral Summary	Aldkindi sprinkle new. Compliance is at 97%. No changes recommended.	x		pass
	Intranasal Rhinitis Agents		No recent/new clinical information. Compliance is good. No changes recommended.	x		pass
Leukotriene Modifiers		No recent/new clinical information. Compliance is good. No changes recommended.	x		pass	

2021 Schedule

September 21st
December 14th

Adjournment

The meeting adjourned at 9:45 AM